Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.

Article  PubMed  Google Scholar 

Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4:36–54.

CAS  PubMed  PubMed Central  Google Scholar 

Rivera-Concepcion J, Uprety D, Adjei AA. Challenges in the use of targeted therapies in non-small cell lung cancer. Cancer Res Treat. 2022;54:315–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vander Velde R, Yoon N, Marusyk V, Durmaz A, Dhawan A, Miroshnychenko D, et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat Commun. 2020;11:2393.

Article  Google Scholar 

Mohanty S, Ovee M, Banerjee M. PDZ domain recognition: Insight from Human Tax-Interacting Protein 1 (TIP-1) interaction with target proteins. Biology. 2015;4:88–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan H, Kapoor V, Nguyen K, Akers WJ, Li H, Scott J, et al. Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers. Oncotarget. 2016;7:43352–62.

Article  PubMed  PubMed Central  Google Scholar 

Kapoor V, Singh AK, Rogers BE, Thotala D, Hallahan DE. PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo. J Control Rel. 2019;298:194–201.

Article  CAS  Google Scholar 

Lewis CD, Singh AK, Hsu FF, Thotala D, Hallahan DE, Kapoor V. Targeting a radiosensitizing antibody-drug conjugate to a radiation-inducible antigen. Clin Cancer Res. 2021;27:3224–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson M, Sharma M, Jamieson C, Henderson JM, Mok MT, Bendall L, et al. Regulation of beta-catenin trafficking to the membrane in living cells. Cell Signal. 2009;21:339–48.

Article  CAS  PubMed  Google Scholar 

Kim WK, Kwon Y, Jang M, Park M, Kim J, Cho S, et al. beta-catenin activation down-regulates cell-cell junction-related genes and induces epithelial-to-mesenchymal transition in colorectal cancers. Sci Rep. 2019;9:18440.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah K, Kazi JU. Phosphorylation-dependent regulation of WNT/Beta-Catenin Signaling. Front Oncol. 2022;12:858782.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3.

Article  PubMed  PubMed Central  Google Scholar 

Singh AK, Dadey DY, Rau MJ, Fitzpatrick J, Shah HK, Saikia M, et al. Blocking the functional domain of TIP1 by antibodies sensitizes cancer to radiation therapy. Biomed Pharmacother. 2023;166:115341.

Article  CAS  PubMed  Google Scholar 

Saikia M, Cheung N, Singh AK, Kapoor V. Role of Midkine in cancer drug resistance: regulators of its expression and its molecular targeting. Int J Mol Sci 2023;24:8739.

Cerezo-Wallis D, Contreras-Alcalde M, Troule K, Catena X, Mucientes C, Calvo TG, et al. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med. 2020;26:1865–77.

Article  CAS  PubMed  Google Scholar 

Ding L, Wang N, Wang Q, Fan X, Xin Y, Wang S. Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration. Cell Death Discov. 2023;9:92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang WL, Hsu YC, Luo CW, Chang SJ, Hung YH, Lai CY, et al. Targeting the CDK7-MDK axis to suppresses irinotecan resistance in colorectal cancer. Life Sci 2024:122914.

Singh AK, Lewis CD, Boas C, Diebolder P, Jethva PN, Rhee A, et al. Development of a [89Zr]Zr-labeled human antibody using a novel phage-displayed human scFv Library. Clin Cancer Res. 2024;30:1293–306.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nabbi A, Riabowol K. Rapid isolation of nuclei from cells in vitro. Cold Spring Harb Protoc. 2015;2015:769–72.

Article  PubMed  Google Scholar 

Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2014;106:djt356.

Article  PubMed  Google Scholar 

Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, et al. Wnt/beta-Catenin signaling and resistance to immune checkpoint inhibitors: from non-small-cell lung cancer to other cancers. Biomedicines 2023;11:190.

Kanamori M, Sandy P, Marzinotto S, Benetti R, Kai C, Hayashizaki Y, et al. The PDZ protein tax-interacting protein-1 inhibits beta-catenin transcriptional activity and growth of colorectal cancer cells. J Biol Chem. 2003;278:38758–64.

Article  CAS  PubMed  Google Scholar 

Zhang J, Yan X, Shi C, Yang X, Guo Y, Tian C, et al. Structural basis of beta-catenin recognition by Tax-interacting protein-1. J Mol Biol. 2008;384:255–63.

Article  CAS  PubMed  Google Scholar 

Persad A, Venkateswaran G, Hao L, Garcia ME, Yoon J, Sidhu J, et al. Active beta-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A. Genes Cancer. 2016;7:368–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Staal FJ, van Noort M, Strous GJ, Clevers HC. Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep. 2002;3:63–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang YK, Huang ZJ, Liu S, Liu YP, Song AA, Song XJ. WNT signaling underlies the pathogenesis of neuropathic pain in rodents. J Clin Invest. 2013;123:2268–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vuong LT, Mlodzik M. Wg/Wnt-signaling-induced nuclear translocation of beta-catenin is attenuated by a beta-catenin peptide through its interference with the IFT-A complex. Cell Rep. 2024;43:114362.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, et al. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci USA. 2001;98:10863–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hao H, Maeda Y, Fukazawa T, Yamatsuji T, Takaoka M, Bao XH, et al. Inhibition of the growth factor MDK/midkine by a novel small molecule compound to treat non-small cell lung cancer. PLoS One. 2013;8:e71093.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishida N, Fukazawa T, Maeda Y, Yamatsuji T, Kato K, Matsumoto K, et al. A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor. Exp Cell Res. 2015;335:197–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masui M, Okui T, Shimo T, Takabatake K, Fukazawa T, Matsumoto K, et al. Novel Midkine Inhibitor iMDK inhibits tumor growth and angiogenesis in oral squamous cell carcinoma. Anticancer Res. 2016;36:2775–81.

CAS  PubMed  Google Scholar 

Ueno M, Kariya R, Gunya S, Cheevapruk K, Okada S. Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest. Leuk Res. 2022;116:106826.

Article  CAS  PubMed  Google Scholar 

Kang HC, Kim IJ, Park HW, Jang SG, Ahn SA, Yoon SN, et al. Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. Cancer Lett. 2007;247:40–47.